Medtronic struck a commercial deal to add Merit's ViaVerte BVNA system to its pain portfolio to capture rising demand for minimally invasive chronic pain treatments. The agreement broadens Medtronic's product offering in pain management and should provide modest near-term revenue upside and strategic benefits for growth in the segment.
Medtronic struck a commercial deal to add Merit's ViaVerte BVNA system to its pain portfolio to capture rising demand for minimally invasive chronic pain treatments. The agreement broadens Medtronic's product offering in pain management and should provide modest near-term revenue upside and strategic benefits for growth in the segment.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
